Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Facial synkinesis~Exclusion Criteria:~* Previous complication from botulinum toxin neuromodulator injection~* Inability to understand or complete the SAQ survey~* Inability to participate in follow-up~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA Injectable Product (Type: ACTIVE_COMPARATOR): onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
- AbobotulinumtoxinA Injectable Product (Type: ACTIVE_COMPARATOR): abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
- Incobotulinumtoxin A Injectable Product (Type: ACTIVE_COMPARATOR): incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).